In an immunotherapy study for advanced NSCLC (aNSCLC), the objective response rate (ORR) for patients with high TMB and high PD-L1 expression was 62.5%, compared to 43.9% for patients with high TMB and low PD-L1 expression and 27.3% for patients with low TMB and high PD-L1 expression (17). The gene discussed is CD274; the disease is non-small cell lung carcinoma.